Therapeutic advances in Dravet syndrome: a targeted li

Expert Review of Neurotherapeutics
20, 1065-1079
DOI: 10.1080/14737175.2020.1801423

Citation Report

#	Article	IF	Citations
1	Advances in the design and discovery of novel small molecule drugs for the treatment of Dravet Syndrome. Expert Opinion on Drug Discovery, 2021, 16, 579-593.	2.5	8
2	Novel therapeutic options for Dravet and Lennox-Gastaut syndrome. Expert Review of Neurotherapeutics, 2021, 21, 1191-1194.	1.4	6
3	A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome. Expert Review of Neurotherapeutics, 2022, 22, 351-364.	1.4	13
5	Canonical transient receptor potential channels and their modulators: biology, pharmacology and therapeutic potentials. Archives of Pharmacal Research, 2021, 44, 354-377.	2.7	10
6	Syndromspezifische Therapien, Impfung gegen Corona und Epileptologie in der DDR. Zeitschrift Fur Epileptologie, 2021, 34, 129-131.	0.2	0
7	Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature. Expert Review of Clinical Pharmacology, 2021, 14, 749-760.	1.3	13
9	Antiepileptic Stiripentol May Influence Bones. International Journal of Molecular Sciences, 2021, 22, 7162.	1.8	2
10	Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany. Epilepsia, 2021, 62, 2518-2527.	2.6	21
11	Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H). Journal of Medicinal Chemistry, 2021, 64, 12228-12244.	2.9	25
12	Screening Platforms for Genetic Epilepsiesâ€"Zebrafish, iPSC-Derived Neurons, and Organoids. Neurotherapeutics, 2021, 18, 1478-1489.	2.1	10
13	Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110311.	1.5	22
14	Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies. CNS Drugs, 2021, 35, 61-83.	2.7	39
15	Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1148-1156.	3.3	10
16	Novel and emerging therapeutics for genetic epilepsies. Expert Review of Neurotherapeutics, 2021, 21, 1283-1301.	1.4	1
17	Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy and Behavior, 2022, 126, 108442.	0.9	9
18	A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. CNS Drugs, 2022, 36, 217-237.	2.7	38
19	Anticonvulsive properties of soticlestat, a novel cholesterol 24â€hydroxylase inhibitor. Epilepsia, 2022, 63, 1580-1590.	2.6	12
21	Rare Neurological Diseases: an Overreview of Pathophysiology, Epidemiology, Clinical Features and Pharmacoeconomic Considerations in the Treating. Serbian Journal of Experimental and Clinical Research, 2021, .	0.2	1

#	Article	IF	Citations
22	New Trends and Most Promising Therapeutic Strategies for Epilepsy Treatment. Frontiers in Neurology, 2021, 12, 753753.	1.1	23
23	Targeted Molecular Strategies for Genetic Neurodevelopmental Disorders: Emerging Lessons from Dravet Syndrome. Neuroscientist, 2023, 29, 732-750.	2.6	0
24	Usage of Genetic Panels in an Adult Epilepsy Clinic. Canadian Journal of Neurological Sciences, 2023, 50, 411-417.	0.3	4
25	Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome. Neurological Research and Practice, 2022, 4, .	1.0	11
26	1,3-Benzodioxole Derivatives Improve the Anti-Tumor Efficiency of Arsenicals. International Journal of Molecular Sciences, 2022, 23, 6930.	1.8	1
27	Nordic treatment guidelines for rare epileptic conditions: A literature review. Brain and Behavior, 2022, 12, .	1.0	1
28	Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications. Journal of Pediatric Health Care, 2022, 36, 479-488.	0.6	3
30	Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. CNS Drugs, 2022, 36, 1079-1111.	2.7	43
31	Interim results of adaptive functioning and neurodevelopment in BUTTERFLY â€“ An observational study of children and adolescents with Dravet syndrome. Epilepsy and Behavior, 2022, 137, 108955.	0.9	2
32	Anti-convulsant Agents: Cannabidiol and Fenfluramine. , 2022, , 3781-3795.		0
33	Characterization of three naturally occurring lignans, sesamol, sesamolin, and sesamin, as potent inhibitors of human cytochrome P450 46A1: Implications for treating excitatory neurotoxicity. Frontiers in Pharmacology, 0, 13, .	1.6	1
34	Emotional experiences of family caregivers of children with Dravet syndrome. Epilepsy and Behavior, 2023, 142, 109193.	0.9	5
35	Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain. Scientific Reports, 2023, 13, .	1.6	2
39	Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Drugs, 2023, 83, 1409-1424.	4.9	7